Voloridge Investment Management LLC Has $8.71 Million Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Voloridge Investment Management LLC grew its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 317.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 201,576 shares of the company's stock after acquiring an additional 153,280 shares during the quarter. Voloridge Investment Management LLC owned about 0.22% of Scholar Rock worth $8,712,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. FMR LLC grew its stake in shares of Scholar Rock by 33.7% during the 4th quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after purchasing an additional 3,439,215 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Scholar Rock by 7.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company's stock valued at $401,231,000 after purchasing an additional 629,315 shares during the last quarter. Vanguard Group Inc. grew its position in Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after acquiring an additional 708,817 shares during the last quarter. Marshall Wace LLP grew its position in Scholar Rock by 1,283.7% in the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock valued at $127,301,000 after acquiring an additional 2,732,546 shares during the last quarter. Finally, Bellevue Group AG grew its position in shares of Scholar Rock by 16.2% during the 4th quarter. Bellevue Group AG now owns 2,510,690 shares of the company's stock worth $108,512,000 after buying an additional 349,487 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Price Performance

NASDAQ:SRRK traded down $1.42 during trading hours on Friday, reaching $28.42. 231,514 shares of the company traded hands, compared to its average volume of 1,265,694. The firm's 50-day moving average is $30.47 and its 200-day moving average is $35.96. The stock has a market cap of $2.70 billion, a P/E ratio of -12.16 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter in the prior year, the business posted ($0.59) earnings per share. Equities research analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Scholar Rock

In other news, insider Tracey Sacco sold 6,500 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the transaction, the insider now owns 71,750 shares of the company's stock, valued at $2,373,490. This represents a 8.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of Scholar Rock stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $35.62, for a total value of $5,068,441.04. Following the completion of the sale, the chief financial officer now directly owns 111,345 shares in the company, valued at $3,966,108.90. This represents a 56.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 154,798 shares of company stock valued at $5,482,238 over the last three months. Company insiders own 13.30% of the company's stock.

Analysts Set New Price Targets

Separately, Wedbush reiterated an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Wednesday, May 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.